Tomeglovir

Research use only, not for human use.

Tomeglovir (BAY 384766) is a potent, highly selective, nonnucleoside inhibitor of cytomegalovirus (CMV) replication.

Tomeglovir (BAY 384766) is a potent, highly selective, nonnucleoside inhibitor of cytomegalovirus (CMV) replication; selectively inhibits not only HCMV strains, including ganciclovir-resistant clinical isolates, but also a number of monkey and rodent cytomegaloviruses.CMV Infection Phase 2 Discontinued.

Tomeglovir (BAY 38-4766) is a potent anti-CMV agent, with IC50s of 0.34 μM and 0.039 μM for HCMV and MCMV. Tomeglovir also suppresses HELF and NIH 3T3 cells, with CC50s of 85 μM and 62.5 μM, respectively. Tomeglovir (BAY 38-4766) inhibits HCMV Davis and various monkey CMV strains with EC50s of 1.03 ± 0.57 μM and < 1 μM.

Tomeglovir (BAY 38-4766; 3, 10, 30, 100 mg/kg, p.o.) dose-dependently reduces MCMV-DNA in salivary glands, livers and kidneys of MCMV-infected NOD-SCID mice, and prolongs the survival of the mice. Tomeglovir (10, 25 and 50 mg/kg) shows antiviral activity in the hollow fiber mouse model. Tomeglovir (BAY 38-4766) shows antiviral activity in SCID mice with MCMV, and the LD50 is >2000 mg/kg in mice and rats.

BAY 38-4766 | BAY 384766

Microbiology/Virology

CMV

CMV

Infection

CMV Infection

233254-24-5

441.546

C23H27N3O4S

>98% (HPLC)

DMSO : ≥ 108 mg/mL 244.60 mM

O=C(NC1=CC=C(NS(=O)(C2=C3C=CC=C(N(C)C)C3=CC=C2)=O)C=C1)C(C)(C)CO

N-(4-(((5-(Dimethylamino)-1-naphthyl)sulfonyl)amino)phenyl)-3-hydroxy-2,2-dimethylpropionamide

(-20℃)

With Ice Pack

≥ 2 years